Zijie Feng

Title: Innovations by Zijie Feng in Tumor-Related Antibody Retrieval

Introduction

Zijie Feng is an accomplished inventor based in Philadelphia, PA. He has made significant contributions to the field of cancer research, particularly in the retrieval of tumor-related antibodies and antigens. His innovative work aims to improve the identification and treatment of various types of tumors.

Latest Patents

Zijie Feng holds a patent for "Compositions and methods for retrieving tumor-related antibodies and antigens." This invention includes a method known as Sequential Tumor-related Antibody and antigen Retrieving (STAR), which efficiently identifies potent antibodies that specifically bind to tumor-related antigens on the surface of tumor cells. Additionally, the patent describes a CAR (Chimeric Antigen Receptor) that incorporates a nanobody, a transmembrane domain, and an intracellular domain, with the nanobody retrieved using the STAR method. Furthermore, the invention includes a CAR T system targeting CD13 for the treatment of acute myeloid leukemia, as well as a CAR T system and ADC (Antibody-Drug Conjugate) that targets CDH17 for treating neuroendocrine tumors and other tumors expressing this antigen, all while maintaining tolerable toxicities.

Career Highlights

Zijie Feng is affiliated with the University of Pennsylvania, where he continues to advance his research and innovations. His work has the potential to significantly impact cancer treatment methodologies and improve patient outcomes.

Collaborations

Zijie Feng collaborates with notable colleagues, including Xianxin Hua and Xin He, who contribute to his research endeavors and enhance the scope of his innovations.

Conclusion

Zijie Feng's innovative work in the field of tumor-related antibody retrieval showcases his commitment to advancing cancer research and treatment. His contributions are paving the way for more effective therapies and improved patient care.